Competition regulators in the UK have approved AstraZeneca PLC’s acquisition of rare disease specialist Alexion Pharmaceuticals Inc., the final green light needed to get the $39bn deal over the line, and the merger should be signed off on 21 July.
AstraZeneca Clears Final Hurdle To Seal Alexion Takeover
Completion Set For 21 July
Antitrust authorities in the UK have followed their counterparts in the EU, Japan and the US to approve the AstraZeneca and Alexion link-up, the biggest pharma M&A deal of 2020.
